Drug intelligence / Profile preview

ALTO-208

Development stage: Unknown
Lead developer: Alto Neuroscience
Modality: Small Molecules
Administration: Oral

Overview

**ALTO-208** is an investigational fixed-dose oral combination of **pramipexole** and **aprepitant** being developed for Parkinson's disease. Pramipexole is a dopamine D3-preferring D2/D3 receptor agonist intended to improve dopaminergic motor symptoms, while aprepitant is a selective neurokinin-1 receptor antagonist used to mitigate nausea and vomiting that can limit pramipexole dose escalation. The program originated at Chase Therapeutics as CTC-413 and was acquired by Alto Neuroscience in 2025; Chase completed a blinded Phase 2a study in patients with Parkinson's disease.

Other names: pramipexole + aprepitant

Targets

DRD3 (Dopamine receptor D3)TACR1 (Neurokinin‑1 Receptor)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on ALTO-208.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALTO-208.

Explore the full profile